GET DAILY SIGNALSMoolec Science (MLEC) Shares Slide -80% Amid Liquidation Proceedings
Key Takeaways
- Moolec Science (MLEC) shares have fallen roughly 80% over the past 30 days, sliding from a close near $4.82 in early October to below $1.00 as a voluntary liquidation moves forward.
- The decline reflects the company's decision to pursue a voluntary winding up, which shareholders approved on October 20, 2026, with approximately 98.4% of votes cast in favor.
- A September 2026 regulatory filing flagged going-concern uncertainty, noted that support from certain shareholders was no longer available, and referenced a disputed winding-up petition.
- A 15-for-1 reverse stock split completed in January 2026 and a very small, thinly traded share count have amplified the stock's day-to-day volatility.
- Over the last quarter, MLEC has fallen roughly 86%, reflecting a sustained deterioration in the company's financial position and the loss of control over Bioceres Crop Solutions Corp. (BIOX).
Company Background and Market Position
Moolec Science SA is a science-based food ingredient company that develops proteins and lipids through molecular farming and precision fermentation. Its pipeline includes animal proteins expressed in crops, such as the Piggy Sooy soybean program, and functional oils like GLASO, a safflower-derived oil rich in gamma-linolenic acid. The company operates across the United States, Europe, and South America and has historically combined the cost structure of crops with the functionality of animal-derived ingredients.
Moolec became the indirect controlling shareholder of Bioceres SA in June 2025 through a share exchange, a transaction intended to broaden its reach into biological agricultural inputs and climate-resilient seed technologies. That combination, however, was followed by mounting financial and accounting challenges, including going-concern warnings and the subsequent loss of control over Bioceres Crop Solutions. Investors have followed MLEC for its exposure to alternative proteins and agricultural biotechnology, but the company's thin float, small market capitalization, and distressed balance sheet have made the stock exceptionally volatile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, MLEC has declined approximately 80%. The shares closed near $4.82 in early October and have since fallen below $1.00, with the most recent intraday price near $0.96. The move was punctuated by a single-session drop of about 47.5% in mid-October, followed by continued selling pressure as liquidation proceedings advanced.
The quarterly picture is even steeper. Compared with a close near $6.73 at the end of July, the stock has declined roughly 86% over the past three months. The trend has been persistently downward rather than a one-off event, reflecting a sequence of regulatory disclosures, financing uncertainty, and, ultimately, the board's and shareholders' decision to wind down the company rather than attempt a turnaround.
Key Drivers Behind the Recent 30-Day Decline
The dominant catalyst was the company's move toward voluntary liquidation. In early October, Moolec filed a Form 6-K calling an extraordinary general meeting to vote on a voluntary winding up under Cayman Islands law, with a special resolution requiring the approval of two-thirds of votes cast. The market responded immediately: shares fell about 47.5% in a single session as investors repriced the prospect that equity holders would receive little or no residual value.
Shareholders subsequently approved the liquidation on October 20, 2026, with roughly 98.4% of votes in favor, and joint voluntary liquidators were appointed. Shortly after the vote, the company dismissed its external auditor, Price Waterhouse & Co S.R.L., a member of the PwC network, and disclosed material weaknesses in internal controls related to business-combination purchase price accounting. Earlier in September, a separate filing had warned of going-concern uncertainty, stated that support from certain shareholders was no longer available, and noted a disputed winding-up petition. Because creditors are paid ahead of equity holders in a liquidation, the lack of any disclosed distribution estimate has left shareholders facing substantial uncertainty, which has weighed heavily on the share price.
Broader Factors Behind the Quarterly Performance
The quarterly decline reflects a broader unraveling that began well before the formal liquidation vote. Moolec had been working through Nasdaq continued-listing conditions tied to minimum bid price and stockholders' equity requirements, and it completed a 15-for-1 reverse stock split in January 2026 to address those thresholds. The company also lost control over Bioceres Crop Solutions, removing a key source of operational scale and strategic rationale.
As the financial position deteriorated, the company's filings increasingly emphasized going-concern risk, while a small share count and limited trading liquidity made each negative disclosure move the stock sharply. The cumulative effect was a steady repricing from the mid-single digits toward penny-stock territory, culminating in the liquidation decision that has defined the most recent stretch of trading. From what I see, the thin float continues to magnify these moves.
What Comes Next for Investors
The path forward for MLEC now depends almost entirely on the liquidation process itself. Investors should monitor the joint liquidators' filings for any disclosure of the company's remaining assets, liabilities, and the timeline for winding down operations. Because creditors rank ahead of shareholders in a liquidation, the key question is whether any residual value will remain for equity holders after obligations are settled, and no distribution estimate has been publicly provided.
Additional factors to watch include the status of the Nasdaq listing, any further regulatory disclosures or amendments to prior filings, and the resolution of the previously reported disputed winding-up petition. Given the company's thin float and distressed financial position, further price swings are possible as the process unfolds. These considerations are informational in nature and are not a recommendation to buy or sell the security. I’m watching this closely as the liquidators provide updates.
Using Tickeron AI Tools in My Research
In my own analysis of volatile names like this one, I often turn to Tickeron’s platform for additional perspective. The AI Trading Bots and related tools help me compare automated strategies across different timeframes and risk levels without replacing my own judgment. It is a practical way to cross-check ideas when markets move quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MLEC's RSI Oscillator is sitting in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MLEC just turned positive on October 27, 2026. Looking at past instances where MLEC's MACD turned positive, the stock continued to rise in 41 of 59 cases over the following month. The odds of a continued upward trend are 69%.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLEC advanced for three days, in 102 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
MLEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MLEC entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.221) is normal, around the industry mean (3.104). P/E Ratio (-0.003) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MLEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement